The ICEfx™ Cryoablation system is a compact and powerful console, offering predictable, reliable performance with seamless therapy delivery and exceptional ease of technical operation BTG plc (LSE: ...

Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized small renal masses, supporting its role as a surgery-sparing local ...

ICESECRET completed five-year follow-up after CT-guided ProSense cryoablation, with imaging-based surveillance for local recurrence and systematic capture of procedure-related complications.

At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of ...

At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained ...

ROCHESTER, Minn. -- A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having ...

For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing – called cryoablation – yields a lower-risk of ...

Cryoablation involves applying extremely cold gas or liquid to an area of cancerous or abnormal tissue. The treatment freezes and destroys the cells. Doctors use cryoablation to treat tumors on the ...

Data supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets where it is approved for kidney cancer, including the U.S. and Europe ...